肿瘤研究与临床
腫瘤研究與臨床
종류연구여림상
CANCER RESEARCH AND CLINIC
2010年
8期
530-533
,共4页
葛楠%林焕新%胡伟汉%苏勇%王汉渝%孙瑞%蔡修宇%卜诗益%张欣%邱孟瑶%张伟%罗素%周溢鑫%金厅
葛楠%林煥新%鬍偉漢%囌勇%王漢渝%孫瑞%蔡脩宇%蔔詩益%張訢%邱孟瑤%張偉%囉素%週溢鑫%金廳
갈남%림환신%호위한%소용%왕한투%손서%채수우%복시익%장흔%구맹요%장위%라소%주일흠%금청
鼻咽肿瘤%放射疗法,调强适形%预后
鼻嚥腫瘤%放射療法,調彊適形%預後
비인종류%방사요법,조강괄형%예후
Nasopharyngeal neoplasms%Radiotherapy,intensity-modulated%Prognosis
目的 分析初治鼻咽癌根治性调强放射治疗(IMRT)的预后.方法 2005年1至11月初诊鼻咽癌患者117例进入分析,其中男81例,女36例,中位年龄42岁(18～76岁).按照1992年福州鼻咽癌分期标准:Ⅰ期11例、Ⅱ期15例、Ⅲ期54例、ⅣA期37例,IMRT计划与实施由PEACOCK系统完成.鼻咽肿瘤体积(GTVnx)处方剂量68 Gy,颈部转移淋巴结(GTVnd)60～66Gy,临床靶体积1(CTV1)60 Gy,临床靶体积2(CTV2)54 Gy.结果 全组随访10.5～59.5个月,中位随访期48个月,3、5年总生存率分别为95.7%和89.7%,无进展生存率分别为91.5%和87.2%,局部区域控制率分别为94.0%和91.5%.单因素分析显示治疗前Karnofsky评分、T分期、1992年福州分期、治疗前血小板和治疗后尿酸水平等因素均影响患者的生存时间,多因素分析显示T分期是影响患者生存时间的独立因素.结论 根治性IMRT显著延长了初治鼻咽癌患者的生存时间,T分期是影响患者生存时间的独立预后因素.
目的 分析初治鼻嚥癌根治性調彊放射治療(IMRT)的預後.方法 2005年1至11月初診鼻嚥癌患者117例進入分析,其中男81例,女36例,中位年齡42歲(18～76歲).按照1992年福州鼻嚥癌分期標準:Ⅰ期11例、Ⅱ期15例、Ⅲ期54例、ⅣA期37例,IMRT計劃與實施由PEACOCK繫統完成.鼻嚥腫瘤體積(GTVnx)處方劑量68 Gy,頸部轉移淋巴結(GTVnd)60～66Gy,臨床靶體積1(CTV1)60 Gy,臨床靶體積2(CTV2)54 Gy.結果 全組隨訪10.5～59.5箇月,中位隨訪期48箇月,3、5年總生存率分彆為95.7%和89.7%,無進展生存率分彆為91.5%和87.2%,跼部區域控製率分彆為94.0%和91.5%.單因素分析顯示治療前Karnofsky評分、T分期、1992年福州分期、治療前血小闆和治療後尿痠水平等因素均影響患者的生存時間,多因素分析顯示T分期是影響患者生存時間的獨立因素.結論 根治性IMRT顯著延長瞭初治鼻嚥癌患者的生存時間,T分期是影響患者生存時間的獨立預後因素.
목적 분석초치비인암근치성조강방사치료(IMRT)적예후.방법 2005년1지11월초진비인암환자117례진입분석,기중남81례,녀36례,중위년령42세(18～76세).안조1992년복주비인암분기표준:Ⅰ기11례、Ⅱ기15례、Ⅲ기54례、ⅣA기37례,IMRT계화여실시유PEACOCK계통완성.비인종류체적(GTVnx)처방제량68 Gy,경부전이림파결(GTVnd)60～66Gy,림상파체적1(CTV1)60 Gy,림상파체적2(CTV2)54 Gy.결과 전조수방10.5～59.5개월,중위수방기48개월,3、5년총생존솔분별위95.7%화89.7%,무진전생존솔분별위91.5%화87.2%,국부구역공제솔분별위94.0%화91.5%.단인소분석현시치료전Karnofsky평분、T분기、1992년복주분기、치료전혈소판화치료후뇨산수평등인소균영향환자적생존시간,다인소분석현시T분기시영향환자생존시간적독립인소.결론 근치성IMRT현저연장료초치비인암환자적생존시간,T분기시영향환자생존시간적독립예후인소.
Objective To analyse the prognosis of 117 newly diagnosed nasopharyngeal carcinoma (NPC) patients underwent intensity modulated radiotherapy (IMRT). Methods From Jan to Nov 2005, 117 NPC patients who were treated by IMRT were enrolled. There were 81 males and 36 females with a median age of 42 years (range 18-76 years). According to Chinese Fuzhou Staging system(1992), 11 cases were Stage I , 15 Stage Ⅱ, 54 Stage Ⅲ and 37 Stage ⅣA. IMRT was carried out with Peacock plan. The prescription dose to the gross target volume(GTVnx) of nasopharyngeal tumor was 68 Gy, that of positive neck lymph nodes (GTVnd) was 60-66 Gy, clinical target volume 1 (CTV1) was 60 Gy, and CTV2 was 54 Gy. Results After a median follow-up time of 48 months (range 10.5-59.5 months), the 3-and 5-year overall survival (OS) rates were 95.7 % and 89.7 %, the disease-free survival (DFS) rates were 91.5 % and 87.2%, and the local-regional control rates were 94.0 % and 91.5 %. Univariate analysis showed the KPS, stage, Fuzhou clinical stage, status of blood platelet before treatment and uric acid after treatment were correlated with OS rate. T stage was the only independent factor of prognosis in the COX stepwise regression model. Conclusion Radical IMRT significantly prolongs the survival of NPC patients. T stage is the only independent prognostic factor for NPC patients.
